Compare 3M Company (MMM) vs TG Therapeutics Inc (TGTX) Price & Performance

3M (MMM) trades at $184.15, up 1.16% on the day, with a bullish technical signal supported by moving averages. The company reported strong Q2 2026 earnings, beating estimates and raising full-year guidance, driven by growth in Safety & Industrial and Transport & Electronics segments. Financial health is solid with a net income margin of 11.9% and robust cash flow, though valuation ratios like P/E of 32.53 appear elevated. Recent news highlights innovation in high-growth verticals and a partnership with Microsoft on EBO technology.

The outlook for MMM is positive due to operational improvements and raised guidance, but risks include high valuation, ongoing litigation, and macroeconomic pressures. Analyst sentiment is mixed with a consensus price target of $173.00 below the current price, suggesting cautious optimism. Investors should weigh strong fundamentals against potential headwinds for balanced decision-making.

TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.

The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.